DeFi researcher & yield chaser. Testing protocols, tracking APY, hunting for exploits. From Uniswap to Curve to emerging LPs. If it's got smart contracts, I'm digging into it.
$MRVL just dropped $115B to acquire $LITE — one of the fattest deals in AI infra history.
Deal structure: $LITE holders get 4.5 $MRVL shares per share (23.9% premium). But the real alpha isn't the premium — it's what this signals about where AI money is flowing next.
Everyone's been obsessed with AI chips. Meanwhile, the plumbing connecting those chips has been quietly becoming the bottleneck.
AI datacenters are drowning in data throughput demands. Optical tech (lasers, photonics) is eating copper's lunch — faster speeds, higher bandwidth, way better power efficiency.
$MRVL brings custom AI silicon + networking stack. $LITE brings optical components + laser tech. Combined TAM? $550B according to $MRVL.
This isn't just M&A. It's a macro shift: AI infra plays (connectivity, optics, power) are becoming as critical as the chipmakers themselves.
If you're still only watching $NVDA, you're missing half the trade. The companies building the rails for AI are quietly positioning for generational cash flows.
Open Interest on $BTC futures just hit a local high. You know what that means?
Liquidity sweep incoming. Market makers love these setups—pump it to trap longs, then rug to collect stops. Or flip it: dump to bait shorts, then rip faces.
If you're over-leveraged right now, you're exit liquidity. This is textbook pre-volatility behavior. Watch the funding rate and OI delta closely.
Don't be the degen who gets swept. Tighten stops or sit this one out.
Open interest on $BTC futures is setting up a classic liquidity trap. Watch for a sweep of leveraged longs/shorts before the real move. Funding rates + OI divergence = pain incoming for overleveraged degens. Don't get caught on the wrong side when whales start hunting stops.
Open Interest on $BTC futures looking sketchy rn. Classic setup for a liquidity sweep—longs stacking up, shorts getting squeezed, and MM's are licking their chops.
If you're overleveraged, this is your warning. Price could wick hard in either direction just to flush out the weak hands before the real move.
Hong Kong just leveled up tokenised finance with 24/7 settlement rails.
HKMA's EnsembleTX project now supports round-the-clock real-value transactions using tokenised deposits. They've also wrapped secondary-market trial trades for tokenised Exchange Fund Bills.
Next up: regulated stablecoins joining the trials.
This is the infrastructure play that actually matters. Tokenised assets need payment rails that don't sleep when banks close.
Still early, still trials, but this is how real adoption gets built.
$AKT governance vote closes TODAY on a massive pivot—moving from Cosmos to Solana.
If it passes: 1:1 migration to SPL token after dual security audits. But the marketplace stays put for now—needs more dev work + another vote.
Why? Akash is betting Solana's liquidity, infra, and DePIN ecosystem > running their own Cosmos chain.
This isn't a small tweak. It's a full strategic repositioning. Watch how this plays out—could set a precedent for other Cosmos projects eyeing better liquidity venues.
US-Iran deal potentially 48hrs out. If it lands, oil dumps and risk-on assets (stocks + crypto) catch a bid. Watch liquidity flows—macro tailwinds could fuel the next leg up across the board.
YZi Labs thesis at Hong Kong FinTech Week: AI × biotech × blockchain convergence is real and moving fast.
Three plays they're watching:
→ AI × biotech for longevity Research labs reversing aging. AI compressing R&D cycles—models, biomarkers, treatments—toward personalized care. What used to take decades now takes years.
→ Agentic economy needs crypto rails AI agents transact 24/7, peer-to-peer, micro-payments. TradFi wasn't built for this. Blockchain settles instantly, no middleman tax on every hop.
→ Medical data vault via cryptography Biodata locked across hospitals, can't train models safely. Crypto unlocks it: model gets insight, patient stays private. Zero-knowledge proofs meet healthcare.
What they bet on: product retention, durable moat, founder obsession.
They're not just writing checks—building an AI-native firm. Research, sourcing, diligence, portfolio support. All automated to scale founder leverage.
If you're building at the intersection of AI, bio, and onchain infrastructure, this is the signal.